| 000 | 01299 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250516233405.0 | ||
| 264 | 0 | _c20150520 | |
| 008 | 201505s 0 0 eng d | ||
| 022 | _a1482-1826 | ||
| 024 | 7 |
_a10.18433/j3wp4f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNanau, Radu M | |
| 245 | 0 | 0 |
_aSafety of anti-tumor necrosis factor therapies in arthritis patients. _h[electronic resource] |
| 260 |
_bJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques _c2014 |
||
| 300 |
_a324-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aNeuman, Manuela G | |
| 773 | 0 |
_tJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques _gvol. 17 _gno. 3 _gp. 324-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18433/j3wp4f _zAvailable from publisher's website |
| 999 |
_c24193489 _d24193489 |
||